Greenwich LifeSciencesGLSI
About: Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Employees: 8
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
5% more funds holding
Funds holding: 39 [Q3] → 41 (+2) [Q4]
0.17% more ownership
Funds ownership: 8.67% [Q3] → 8.84% (+0.17%) [Q4]
20% less capital invested
Capital invested by funds: $16.4M [Q3] → $13.1M (-$3.34M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen 31% 1-year accuracy 53 / 171 met price target | 276%upside $39 | Buy Maintained | 21 Apr 2025 |
Financial journalist opinion









